Immunology and inflammation biotech company Bambusa (BBTX.US) prices IPO at $15-17 per share, aims to raise $150 million.
Bambusa Therapeutics plans to raise 150 millions USD by issuing 9.4 million shares at a price range of 15 to 17 USD per share.
According to Golden Ten Data, Bambusa Therapeutics, a biotechnology company focused on immunology and inflammation, announced on Monday the terms for its initial public offering (IPO). The company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Based on the midpoint of the proposed pricing range, Bambusa Therapeutics’ fully diluted market capitalization will reach $837 million. The company plans to list on Nasdaq under the ticker symbol “BBTX.” The IPO is expected to be priced during the week of October 26, 2026.
Headquartered in Boston, Massachusetts, USA, Bambusa Therapeutics is a clinical-stage biotechnology company developing long-acting bispecific antibodies for immunology and inflammatory diseases. Its core drug candidate, BBT001, targets IL-4Rα and IL-31, is currently undergoing a Phase I trial for atopic dermatitis, with initial proof-of-concept data released in July 2026; in addition, the drug is also in a Phase IIa trial in China for chronic spontaneous urticaria.
The company’s second candidate, BBT002, targets IL-4Rα and IL-5, and is currently in Phase I to IIa trials for chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps, and asthma.
In addition, the company has two preclinical projects: BBT003, which targets TL1A and IL-23p19 for the treatment of inflammatory bowel disease; and BBT004, a bispecific antibody designed to deplete B cells for the treatment of autoimmune diseases. All of Bambusa Therapeutics' core assets are licensed from the Chinese subsidiary of the German biotechnology company BioNTech.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After Jensen's resignation, the "Big Short" doubles down on shorting tech stocks! Warns the AI boom may turn into a "bull trap"
Michael Burry increased his short positions following Huang Renxun's resignation. He compared Nasdaq’s October peak to the top of the 2000 internet bubble. On November 12th, he doubled his put option positions on the Nasdaq 100, with expiry set for early 2027, and rebuilt put options on the VanEck Semiconductor Index. He directly warned investors to "exit the market" and predicted a significant correction in chip stocks before mid-2027.
Tesla (TSLA.US) Cybercab limited pre-orders open: priced at $29,990, with an additional monthly operating fee of $299
According to reports, Tesla has invited select customers to reserve the Cybercab, taking a step toward launching this self-driving model to general consumers.
Fed Vice Chair Sets the Tone: Inflation Is the "Most Important Signal," Interest Rate Decisions Depend on It
Federal Reserve Vice Chair Philip Jefferson stated that when policymakers consider whether to raise interest rates further, inflation has become the most important metric.
Elon Musk Leads Petition! Silicon Valley Supports Jensen Huang as Tens of Thousands Call for the Return of the Founder
Elon Musk has publicly co-signed a petition in support of Jensen Huang’s return to NVIDIA. The number of signatures on the petition website has surpassed 14,000, causing the site to almost crash due to a surge in traffic. What is raising further alarm in the capital markets is that NVIDIA’s core engineers have made collective statements, warning that if senior management mishandles the situation, key technical talent may leave, potentially undermining NVIDIA’s competitive moat.
Crypto prices
More
